The 4 most recent market catalysts affecting $RVNT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Roivant Sciences shares are trading higher after the company announced its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease met its primary endpoint.
This headline represents a significant corporate catalyst for Roivant Sciences. The successful Phase 2 trial for mosliciguat de-risks a key asset in their pipeline, suggesting a hi…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Roivant Announces Results From Its Phase 2 PHocus Clinical Trial Evaluating Mosliciguat For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; PHocus Met Its Primary Endpoint, Demonstrating Clinically Meaningful And Statistically Significant Placebo-Adjusted Reduction In Pulmonary Vascular Resistance
Roivant's announcement details highly successful Phase 2 clinical trial results for mosliciguat in PH-ILD, a severe and underserved condition. The drug demonstrated a remarkable 56…
Sep 7, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Roivant Announced That Results From The Phase 2 Phocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (Ph-ild) Will Be Presented At The European Respiratory Society International Congress 2026 On Tuesday, September 8, 2026
The announcement of Phase 2 study results for Mosliciguat is a significant corporate catalyst for Roivant Sciences (RVNT). The impact score is 75 because Phase 2 results are crucia…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 85
Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. Immediately
The FDA approval of LISRAYA for dermatomyositis is a major positive catalyst for Roivant Sciences (RVNT). As the first targeted therapy for this disease, it grants Priovant (a Roiv…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.